Results 101 to 110 of about 3,169,653 (411)

IL-1Ra Protects Hepatocytes from CCl4-Induced Hepatocellular Apoptosis via Activating the ERK1/2 Pathway

Pharmaceutical Fronts, 2020
Interleukin-1 receptor antagonist is an important acute-phase protein and an immune mediator, and its expression is associated with the development of hepatitis or acute liver failure.
Ying Zheng, Xinyi Xiao, Zhuoyi Yang, Meiqi Zhou, Hui Chen, Siyi Bai, Jianwei Zhu, Yunsheng Yuan   +7 more
doaj   +1 more source

Indometh acin-antihistamine combination for gastric ulceration control [PDF]

, 1980
An anti-inflammatory and analgesic composition containing indomethacin and an H2 histamine receptor antagonist in an amount sufficient to reduce gastric distress caused by the indomethacin was developed.
Brown, P. A., Vernikos, J.
core   +1 more source

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

Behavioral and pharmacological characterization of a mouse model of palatable diet alternation [PDF]

, 2017
Obesity and eating disorders represent a severe problem in Western societies. Both the increased availability of highly palatable foods and dieting are major risk factors contributing to the epidemic disorders of feeding. The purpose of this study was to
Schlain, Gabrielle Star
core  

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist

Nature, 2011
The parasympathetic branch of the autonomic nervous system regulates the activity of multiple organ systems. Muscarinic receptors are G-protein-coupled receptors that mediate the response to acetylcholine released from parasympathetic nerves.
K. Haga, A. Kruse, H. Asada, Takami Yurugi-Kobayashi, M. Shiroishi, Cheng Zhang, W. Weis, T. Okada, B. Kobilka, T. Haga, Takuya Kobayashi   +10 more
semanticscholar   +1 more source

Peptide Antagonism and T Cell Receptor Interactions with Peptide-MHC Complexes [PDF]

, 1998
We describe antagonist peptides that specifically inhibit cytolytic activity of T cell clones and lines that express the antigen-specific receptor of CD8+ T lymphocyte clone 2C, which recognizes peptides in association with syngeneic (Kb) and allogeneic (
Brunmark, Anders, Eisen, Herman N., Ploegh, Hidde L., Sykulev, Yuri, Vugmeyster, Yulia   +4 more
core   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

GABAA receptor signalling mechanisms revealed by structural pharmacology

Nature, 2019
Type-A γ-aminobutyric (GABAA) receptors are ligand-gated chloride channels with a very rich pharmacology. Some of their modulators, including benzodiazepines and general anaesthetics, are among the most successful drugs in clinical use and are common ...
S. Masiulis, Rooma Desai, T. Uchański, I. S. Martin, D. Laverty, D. Karia, T. Malinauskas, J. Zivanov, E. Pardon, A. Kotecha, J. Steyaert, K. Miller, A. Aricescu   +12 more
semanticscholar   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source